AbbVie banishes the ghost of Stemcentrx
Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.
Gilead ups its bet on Arcellx and BCMA
The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.
Cell therapy groups double down on speedy manufacturing
Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.
Schrödinger jumps on the PRMT5 bandwagon
Meanwhile, Bristol Myers Squibb hands back two mystery projects.
Cellectis gets another bailout
Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.
Merck KGaA takes another shot at PARP1
But today’s deal with Jiangsu Hengrui doesn’t mean that the group is turning away from an earlier tie-up with Nerviano.
After failing to get Seagen Merck turns to Daiichi
In paying $5.5bn for immediate rights to three Daiichi Sankyo assets Merck & Co has made its biggest bet on ADCs to date.
